ArticleJTO clinical and research reports2021

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042.

Aaron S Mansfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.